Title: Case Report on Pulmonary Mucormycosis
Authors: Dr Srikant Sharma, Dr Satyanarayan Mohapatra, Dr Nisarg Patel
DOI: https://dx.doi.org/10.18535/jmscr/v7i10.87
Abstract
Mucormycosis is a life-threatening infection occurs in immunocompromised patients. Increasing prevalence of diabetes mellitus, cancer, and organ transplantation, the number of mucormycosis is increasing. Despite antifungal, high risk surgery therapy, the overall mortality rate is high.
We are reporting a case of 77 years old male, referred to a tertiary care hospital with non resolving pneumonitis, uncontrolled blood sugar and deranged renal function. He was on multiple antibiotics from last 10 days and was later found to have pulmonary Mucormycosis.
Keywords: Pulmonary, Mucormycosis, Fungal infection, Amphotericin.
References
- Jeong, W.; Keighley, C.; Wolfe, R.; Lee, W.L.; Slavin, M.A.; Kong, D.C.M.; Chen, S.C.A. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 2019, 25, 26–34. [CrossRef] [PubMed]
- Prakash, H.; Ghosh, A.K.; Rudramurthy, S.M.; Singh, P.; Xess, I.; Savio, J.; Pamidimukkala, U.; Jillwin, J.; Varma, S.; Das, A.; et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med. Mycol. 2018. [CrossRef] [PubMed]
- Hamillos G, Samonis G, kontoyiannis DP. Pulmonary mucormycosis. Semin Respir Crit Care Med.all 2011; 32(6):693–702. [PubMed: 22167397]
- Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41(5):634–653. [PubMed: 16080086]
- Tedder, M.; Spratt, J.A.; Anstadt, M.P.; Hegde, S.S.; Tedder, S.D.; Lowe, J.E. Pulmonary mucormycosis: Results of medical and surgical therapy. Ann. Thorac. Surg. 1994, 57, 1044–1050. [CrossRef]
- Lee, F.Y.; Mossad, S.B.; Adal, K.A. Pulmonary mucormycosis: The last 30 years. Arch. Intern. Med. 1999, 159, 1301–1309. [CrossRef] [PubMed].
- Feng, J.; Sun, X. Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome. Infection 2018, 46, 503–512. [CrossRef]
- Smith JA, Kauffman CA. Pulmonary fungal infections. Respirology. 2012; 17(6):913–926. [PubMed: 22335254
- Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. Hematology Am Soc Hematol Educ Program 2013 2013:423–7.
- Spellberg B, Ibrahim AS. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep.
- Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Golberg R, Spellberg B. Combination polyene-caspofungin treatment of rhinoorbital-cerebral mucormycosis. Clin Infect Dis. 2008; 47(3):364–371. [PubMed: 18558882]
- Donnelley M.A., Zhu E.S., Thompson G.R. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect. Drug Resist. 2016;9:79–86. [PMC free article] [Pub Med] [Google Scholar].
- Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol. 2012; 50(6):611–618. [Pub Med:22435877].